Owlet has recently reported its Q2 2026 earnings and held earnings calls providing operational and financial updates. The company continues to disclose financial results and business highlights through primary news sources.

• Owlet reported Q2 2026 earnings and revenues that exceeded prior expectations, as detailed in earnings call highlights [N1].
• The company held a Q2 2026 earnings call discussing operational performance and financial results [N1].
• Owlet reported a net loss of $620,000 and EPS of -$0.05 for Q2 2026, with liquidity ratios indicating a current ratio of 1.64 and cash ratio of 0.57 as of June 30, 2026 [S2].
• Owlet's Q1 2026 earnings call and transcript provided insights into the company's financial performance and strategic initiatives [N5][N6].
• The company reported a Q1 2026 loss but topped revenue expectations, indicating some revenue strength despite profitability challenges [N7].

Owlet benefits from a leadership team with extensive experience in healthcare and technology sectors, including a CEO who co-founded the company and has overseen its growth. The company maintains a solid liquidity position with a current ratio of 1.64 as of June 30, 2026, and continues to provide regular financial and operational updates through earnings calls and SEC filings. The board's composition with diverse expertise may support strategic decision-making and operational resilience.

Owlet reported a net loss of $620,000 for Q2 2026 and negative earnings per share, indicating ongoing profitability challenges. The company operates in a competitive environment where sustaining growth and profitability may be difficult. The absence of detailed revenue figures in the provided data limits visibility into top-line performance. Risks disclosed in SEC filings, while not materially changed recently, remain relevant to the company's financial condition and operational execution.

Owlet's moat is supported by its leadership's deep experience in healthcare technology and its established presence since 2012. The company's board includes members with significant backgrounds in healthcare, technology, and finance, which may contribute to strategic oversight and operational execution. Owlet's product development and market presence, while not detailed here, are implied by its ongoing public reporting and investor communications. The company's liquidity position and governance structure provide a foundation for sustaining operations and potential competitive positioning.

• Profitability Risk: Owlet reported a net loss and negative earnings per share for Q2 2026, indicating challenges in achieving profitability.
• Liquidity and Financial Condition: While Owlet has a current ratio of 1.64, ongoing losses could pressure liquidity if not managed carefully.
• Market and Competitive Risks: Owlet operates in a competitive healthcare technology market, which may impact its ability to sustain growth and market share.
• Regulatory and Compliance Risks: As a public company, Owlet is subject to extensive regulatory requirements and must maintain compliance to avoid penalties or reputational damage.

• Owlet, Inc. is a Delaware corporation with principal executive offices in Lehi, Utah.
• The company is listed on the New York Stock Exchange under the ticker OWLT.
• Owlet's Class A common stock had approximately 28.16 million shares outstanding as of March 2, 2026.
• The company filed an amended annual report on Form 10-K/A for the fiscal year ended December 31, 2025, which included detailed disclosures on directors, executive officers, corporate governance, and executive compensation [S1].
• Owlet's board of directors includes members with significant experience in healthcare, technology, finance, and venture capital, including the CEO Kurt Workman who co-founded the company in 2012 and has served in various leadership roles [S1].
• The company filed a Form 10-Q for the quarter ended June 30, 2026, disclosing financial metrics including cash and equivalents of $30.9 million, current assets of $88.3 million, current liabilities of $53.8 million, a current ratio of 1.64, and a cash ratio of 0.57 as of June 30, 2026 [S2].
• Owlet reported a net loss of $620,000 and basic and diluted EPS of -$0.05 for the quarter ended June 30, 2026 [S2].
• Owlet's recent news coverage includes detailed earnings call highlights and financial results for Q1 and Q2 2026, indicating ongoing operational updates and financial performance disclosures [N1][N2][N5][N6][N7].
• The company has publicly disclosed risk factors in its 10-K and 10-K/A filings, with no material changes reported in the latest 10-Q [S2].